Context Therapeutics® will participate in HC Wainwright

0

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecological cancers, announced today that Chief Executive Officer Martin Lehr will participate in a fireside chat during HC Wainwright 24e Annual Global Investment Conference to be held virtually and in person September 12-14, 2022 in New York City. The Fireside Chat will be available on demand to conference attendees beginning September 12 at 7 a.m. ET.

The company will be available in person in New York to participate in one-on-one meetings in conjunction with the conference. Conference details can be found here: https://hcwevents.com/annualconference/.

About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for women’s cancers. The Company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways. Onapristone Extended-Release (ONA-XR), a new, potent and selective first-in-class progesterone receptor antagonist, is currently in three Phase 2 trials and one Phase 1b/2 trial in hormone-induced breast, ovarian and endometrial cancers. Context and The Menarini Group (Menarini) have also entered into a clinical trial collaboration and supply agreement for a Phase 1b/2 proof-of-concept clinical trial evaluating ONA-XR in combination with Selective Estrogen Receptor Degrader ( SERD) oral Menarini, elacestrant. Context is also developing a Claudin 6 (CLDN6) x CD3 selective bispecific antibody for CLDN6 positive tumors, currently in preclinical development. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com or follow the company on Twitter and LinkedIn.

Forward-looking statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor under the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical facts, included in this press release regarding strategy, future operations, outlook, plans and management objectives, including words such as “may”, “will”, “expect”, “anticipate”, “plan “, “intend” and similar expressions (as well as other words or expressions referring to future events, conditions or circumstances) are forward-looking statements. These include, but are not limited to, statements regarding (i) the ability of the Company and its employees to attend and present at conferences, (ii) the results of our clinical trials, (iii) the potential benefits product candidates, (iv) probability data will support future development, and (v) the likelihood of obtaining regulatory approval for our product candidates. The forward-looking statements contained in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and therefore we cannot assure you that our plans, intentions , expectations or strategies will be met or reached. Other factors that could cause actual results to differ from those expressed or implied by the forward-looking statements in this press release are discussed in our filings with the United States Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Media Contact:
Gina Cestari
6 degrees
917-797-7904
[email protected]

Contact with Investor Relations:
Yonker wool
Edison Group
[email protected]

Share.

About Author

Comments are closed.